文献速递胃肠动力与功能性疾病胰腺与胆道疾病

艾沙度林治疗肠易激综合征后胰腺炎风险

Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-08-10

该研究从联邦不良事件报告系统提取2016年1月至9月艾沙度林相关报告,分析胰腺炎发生频率。597份报告中胰腺炎占16.4%,53例需住院;其他药物相关胰腺炎比例显著更低。结论确认艾沙度林相关胰腺炎风险,至少半数需住院及近期2例死亡报告应促使重新评估其风险获益比。

要点

  • 597份艾沙度林不良事件报告中胰腺炎占16.4%,53例需住院。
  • 其他药物相关胰腺炎比例显著更低:洛哌丁胺0.3%、地芬诺酯0.4%、羟考酮0.2%、利福昔明0.5%。
  • 至少半数胰腺炎病例需住院及近期2例死亡报告应促使重新评估艾沙度林风险获益比。

核心结论

  • 在联邦不良事件报告系统的艾沙度林报告中,确认了先前报道的艾沙度林相关胰腺炎风险。
  • 至少半数胰腺炎病例需住院及近期2例死亡报告应促使重新评估该药的风险获益比。

研究设计与样本

  • 从联邦不良事件报告系统提取2016年1月至9月提交的艾沙度林报告,收集患者年龄、性别、事件日期、报告实体、药物、剂量、可疑角色、治疗指征和结局。
  • 使用κ2检验、Kruskal-Wallis秩检验和方差分析比较艾沙度林与止泻药、羟考酮和利福昔明的数据,P<.05为统计学显著。

主要发现

  • 597份艾沙度林相关不良事件报告中,胰腺炎占16.4%,53例需住院。
  • 其他药物相关胰腺炎比例显著更低:洛哌丁胺0.3%、地芬诺酯0.4%、羟考酮0.2%、利福昔明0.5%,其中75%的报告未认为该药为因果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The Food and Drug Administration approved eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome despite cases of pancreatitis in early stage trials. We investigated the frequency of pancreatitis attributed to eluxadoline in postmarketing surveillance. METHODS: We extracted reports on eluxadoline submitted to the Federal Adverse Event Reporting System from January through September 2016. We collected data on patient age and sex, event date, reporting entity (consumer, physician, pharmacist, legal worker, or other), medications, dosages, presumed role in the event (coinciding, primary, or secondary suspect), treatment indication, and outcome (death, life threatening, hospitalization, disability, or other).We compared data for eluxadoline with data from antidiarrheals, oxycodone, and rifaximin using the κ2 test, Kruskal-Wallis rank test, and analysis of variance; findings with P < .05 were considered statistically significant. RESULTS: Pancreatitis accounted for 16.4% of the 597 reports of adverse events linked to eluxadoline; 53 cases required hospitalization. Pancreatitis was listed as treatment complication of other agents in significantly lower proportions of cases (loperamide, 0.3%; diphenoxylate, 0.4%; oxycodone, 0.2%; rifaximin, 0.5%), with 75% of these submissions not considering the agent as causal. CONCLUSIONS: In an analysis of reports on eluxadoline submitted to the Federal Adverse Event Reporting System, we confirmed a previously reported risk of pancreatitis associated with eluxadoline. The need for hospitalization in at least half of these instances and a recent report of 2 fatalities should prompt reassessments of the agent's risk-benefit ratio.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Gawron AJ, Bielefeldt K. Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline. Clin Gastroenterol Hepatol. 2017. PMID: 28804032. doi:10.1016/j.cgh.2017.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。